1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA-Cancer J Clin 2020;70, (1), 7-30.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA-Cancer J Clin 2021;71, (3), 209-249.
3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009, 374, (9685), 239-49.
4. Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA-Cancer J Clin 2020, 70, (5), 404-423.
5. Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol 2020, 3, (6), 728-738.
6. Lee HW, Chung W, Lee H-O, Jeong DE, Jo A, Lim JE, et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med 2020, 12, (1), 47-47.
7. Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics 2017, 7, (14), 3585-3594.
8. Crispen PL, Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother 2020, 69, (1), 3-14.
9. Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM,et al. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunol Res 2019, 7, (6), 923-938.
10. Galluzzi L, Green DR. Autophagy-Independent Functions of the Autophagy Machinery. Cell 2019, 177, (7), 1682-1699.
11. Poillet-Perez L, White E. Role of tumor and host autophagy in cancer metabolism. Genes Dev 2019, 33, (11-12), 610-619.
12. Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer 2020, 19, (1), 020-1138.
13. Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci 2019, 134, 116-137.
14. Li F, Guo H, Yang Y, Feng M, Liu B, Ren X, et al. Autophagy modulation in bladder cancer development and treatment (Review). Oncol Rep 2019, 42, (5), 1647-1655.
15. Li F, Teng H, Liu M, Liu B, Zhang D, Xu Z, et al. Prognostic Value of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer. Front Oncol 2020, 10, 1302-1302.
16. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43, (7), e47-e47.
17. Wang NN, Dong J, Zhang L, Ouyang D, Cheng Y, Chen AF, et al. HAMdb: a database of human autophagy modulators with specific pathway and disease information. J Cheminform 2018, 10, (1), 018-0289.
18. Wang P, Wang Y, Hang B, Zou X, Mao JH. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget 2016, 7, (34), 55343.
19. Wilkerson MD, Hayes DN.ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26, (12), 1572-3.
20. Linderman GC, Steinerberger S. Clustering with t-SNE, provably. SIAM J Math Data Sci 2019, 1, (2), 313-332.
21. Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010, 1, (4), 274-278.
22. Dennis GJr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4, (5), P3.
23. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013, 4, 2612.
24. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015, 15, (1), 25-41.
25. Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol 2020, 38, (8), 1895-1904.
26. Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett 2016, 380, (1), 205-15.
27. Wang F, Tang J, Li P, Si S, Yu H, Yang X, et al. Chloroquine Enhances the Radiosensitivity of Bladder Cancer Cells by Inhibiting Autophagy and Activating Apoptosis. Cell Physiol Biochem 2018, 45, (1), 54-66.
28. Hu B, Wang Z, Zeng H, Qi Y, Chen Y, Wang T, et al. Blockade of DC-SIGN(+) Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer. Cancer Res 2020, 80, (8), 1707-1719.
29. Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G.Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling. P Natl Acad Sci USA 2020, 117, (31), 18627-18637.
30. Coleman OI, Lobner EM, Bierwirth S, Sorbie A, Waldschmitt N, Rath E, et al. Activated ATF6 Induces Intestinal Dysbiosis and Innate Immune Response to Promote Colorectal Tumorigenesis. Gastroenterology 2018, 155, (5), 1539-1552.
31. Zhang HH, Li C, Ren JW, Liu L, Du XH, Gao J, et al. OTUB1 facilitates bladder cancer progression by stabilizing ATF6 in response to endoplasmic reticulum stress. Cancer Sci 2021, 112, (6), 2199-2209.
32. Meng J, Liu K, Shao Y, Feng X, Ji Z, Chang B, et al. ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy. Cell Death Dis 2020, 11, (2), 020-2327.
33. Sharif T, Ahn DG, Liu RZ, Pringle E, Martell E, Dai C,et al. The NAD(+) salvage pathway modulates cancer cell viability via p73. Cell Death Differ 2016, 23, (4), 669-80.
34. Zhang K, Zhou B, Zhang P, Zhang Z, Chen P, Pu Y, et al. Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. Tumour Biol 2014, 35, (5), 4031-40.
35. Chen CH, Changou CA, Hsieh TH, Lee Y C, Chu CY, Hsu KC, et al. Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. Clin Cancer Res 2018, 24, (5), 1176-1189.
36. Chen CH, Hsieh TH, Lin YC, Liu YR, Liou JP, Yen Y. Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells. Cancers 2019, 11, (9), 1345-1358.